

al Application No-PCT/GB 03/02936

Relevant to claim No.

A. CLASSIFICATION OF SUBJECT MATTER
1PC 7 G01N33/564 G01N33/569

C. DOCUMENTS CONSIDERED TO BE RELEVANT

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 GO1N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

Citation of document, with indication, where appropriate, of the relevant passages

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

Х	WO 00 26248 A (ISIS INNOVATION AJIT (GB); PATHAN ANSAR AHMED 11 May 2000 (2000-05-11)		1-5, 7-10,12, 14-23, 27,50, 51,53, 57-68,
Υ	page 3, line 1-13; claims 1-22 2,3	; examples	71,72, 92,93 24-26, 29-47, 54-56, 74-89
		-/	
		-/	
[V] E.M	her documents are listed in the continuation of box C.	Y Patent family members are listed	In approx
<u> </u>		X Patent family members are listed	in amex.
"A" docum	ent defining the general state of the art which is not defining the general state of the art which is not dered to be of particular relevance document but published on or after the international	*T* later document published after the inte or priority date and not in conflict with cited to understand the principle or th invention *X* document of particular relevance; the or	the application but eory underlying the
filing o	date ent which may throw doubts on priority claim(s) or	cannot be considered novel or canno involve an inventive step when the do	t be considered to
citatio "O" docum	is cited to establish the publication date of another on or other special reason (as specified) nent referring to an oral disdosure, use, exhibition or means	"Y" document of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvious.	ventive step when the ore other such docu-
P° docum- laler t	ent published prior to the international filing date but han the priority date claimed	in the art. "&" document member of the same patent	tamly
Date of the	actual completion of the international search	Date of mailing of the international se	arch report
8	January 2004	20/01/2004	
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl,	Authorized officer Diez Schlereth, D	
	Fax: (+31-70) 340-3016	Diez Schiereth, D	



Interni al Application No PCT/GB 03/02936

		101/45 03	3/ 02330
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with Indication, where appropriate, of the relevant passages		Relevant to claim No.
Y	PATHAN A A ET AL: "DIRECT EX VIVO ANALYSIS OF ANTIGEN-SPECIFIC IFN-GAMMA-SECRETING CD4 T CELLS IN MYCOBACTERIUM TUBERCULOSIS-INFECTED INDIVIDUALS: ASSOCIATIONS WITH CLINICAL DISEASE STATE AND EFFECT OF TREATMENT" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 167, no. 9, 1 November 2001 (2001-11-01), pages 5217-5225, XP001093768 ISSN: 0022-1767 the whole document		24-26, 29-47, 54-56
Y	LALVANI A ET AL: "Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells" LANCET THE, LANCET LIMITED. LONDON, GB, vol. 357, no. 9273, 23 June 2001 (2001-06-23), pages 2017-2021, XP004247721 ISSN: 0140-6736 abstract		74-89
A	WO 01 04151 A (STATENS SERUMINSTITUT ;ANDERSEN PETER (DK); SKJOET RIKKE (DK)) 18 January 2001 (2001-01-18) the whole document		1-94
Ρ,Χ	WO 02 054072 A (ISIS INNOVATION ;LALVANI AJIT (GB)) 11 July 2002 (2002-07-11)		1-5, 7-10, 12-20, 22-27, 29-40, 42-49, 51-54, 57-72, 74,77, 79-82, 84-93
	the whole document		01-93



tional application No. PCT/GB 03/02936

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Claims 20-21, 24, 26, 29-50, 53-57, 59-70, 74-78 and 80-91 include diagnostic/therapy methods involving the treatment of the human/animal body covered by the provisions of Rule 67.1 (iv) PCT.
2. X	Claims Nos.: 22–25, 27–28, 50–51, 71–73, 92–94 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
з. 🔲	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Int	ernational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. X	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Hemar	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

International Application No. PCTGB 03 D2936

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 22-25, 27-28, 50-51, 71-73, 92-94

Present claims 22-25, 27-28, 50-51, 71-73 and 92-94 relate to an extremely large number of possible products which may be obtained from apparently any pathogen. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the products claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to peptide/antigen products obtained from Mycobacterium tuberculosis.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-94

diagnostic methods and kits

- 1.1. Claims: 1-28.

 methods of diagnosis/therapy in which T-cells recognize proteins derived from a pathogen and having at least 30 amino acids to a greater extent than one or more peptide epitope from the pathogen agent, and products and kits thereof.
- 1.2. Claims: 29-52 methods of diagnosis/therapy in which T-cells recognize antigens derived from a pathogen at a first and a second time point after exposure to the pathogen, and products and kits thereof.
- 1.3. Claims: 53-94 methods of diagnosis/therapy in which an increased level of T-cells recognize mycobacterial antigens, and products and kits thereof.

The present application lacks unity (Rule 13.1 PCT) because the above mentioned groups of inventions do not appear to be linked by a common single novel and inventive concept within the sense of Rule 13.2 PCT.

Please note that all inventions mentioned under item 1, although not necessarily linked by a common inventive concept, could be searched without effort justifying an additional fee.





INTERNATIONAL SEARCH REPORT

Intern 31 Application No PCT/GB 03/02936

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0026248	A	A 11-05-2000	AU	6480999 A	22-05-2000
			BR	9915055 A	07-08-2001
			CA	2348475 A1	11-05-2000
			CN	1350546 T	22-05-2002
			ΕP	1144447 A2	17-10-2001
			WO	0026248 A2	11-05-2000
			JP	2002532064 T	02-10-2002
			ZA	200103356 A	24-01-2002
WO 0104151	A	18-01-2001	AU	5966400 A	30-01-2001
			CA	2378763 A1	18-01-2001
			WO	0104151 A2	18-01-2001
			ΕP	1200466 A2	02-05-2002
			JP	2003510018 T	18-03-2003
WO 02054072	Α	11-07-2002	CA	2433236 A1	11-07-2002
			WO	02054072 A2	11-07-2002